ChemGenex Pharmaceuticals

Cephalon announces takeover bid for ChemGenex

Wednesday, March 30, 2011

Cephalon and ChemGenex Pharmaceuticals announced that Cephalon’s wholly-owned subsidiary, Cephalon CXS Holdings, intends to make a takeover bid for ChemGenex. ChemGenex is a hematology-focused Australian biopharmaceutical company developing its lead product candidate, Omapro, for the treatment of chronic myeloid leukemia (CML) patients. Omapro recently completed phase III clinical trials and ChemGenex plans to file a new drug application with the FDA in the second half of 2011.

[Read More]